Stereotaxis, Inc. (AMEX: STXS) is a Healthcare company (Medical - Instruments & Supplies) with a market capitalization of $88M. The Maz Rating grades it against the other companies in its sector.
Stereotaxis, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $0.88, Stereotaxis, Inc. trades at 2.7x sales and 4.0x book value. Over the last twelve months it generated about $33M of revenue and a net loss of $26M. It runs a gross margin of 52.5%, an operating margin of -69.4% and a net margin of -70.9%. It shows return on equity of -115.8%, return on invested capital of -42.3% and a free cash flow yield of -17.5%. On the balance sheet: a debt-to-equity ratio of 0.37 and a current ratio of 1.08. Over the past 52 weeks the share price ranged from $0.80 to $2.86, with a beta of 1.40.
Stereotaxis, Inc. does not currently pay a dividend.
12 Wall Street analyst ratings cover the stock: 12 Buy, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Stereotaxis, Inc. designs, manufactures and markets robotic magnetic navigation systems for use in a hospital's interventional surgical suite to enhance the treatment of arrhythmias and coronary artery disease. Its products include the Genesis RMN System, the Odyssey Solution, and related devices. The firm also offers the Stereotaxis Imaging Model S x-ray System. The company was founded in June 1990 and is headquartered in St. Louis, MO.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
Yes. As of September 2026, Stereotaxis, Inc. (STXS) is classified as HALAL by Maz Vantage: it passes all 5 published Shariah screening standards it was tested against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 2.09% / 30% · (Cash+Inv) / Mkt Cap (36m) 4.80% / 30% · Interest income / Revenue 0.37% / 5% | Pass |
| S&P Global | Debt / Mkt Cap (36m) 2.09% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 3.36% / 33% · Receivables / Mkt Cap (36m) 4.73% / 49% · Interest income / Revenue 0.37% / 5% | Pass |
| Dow Jones | Debt / Mkt Cap (24m) 2.09% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 3.36% / 33.33% · Receivables / Mkt Cap (24m) 4.73% / 33.33% · Interest income / Revenue 0.37% / 5% | Pass |
| MSCI | Debt / Avg Assets (4Q) 1.01% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 17.4% / 33.33% · Receivables / Avg Assets (4Q) 16.1% / 33.33% · Interest income / Revenue 0.37% / 5% | Pass |
| FTSE | Debt / Total Assets 3.01% / 33.33% · (Cash+ST Inv) / Total Assets 4.84% / 33.33% · (Cash+Recv) / Total Assets 11.6% / 33.33% · Interest income / Revenue 0.37% / 5% | Pass |
Yes. As of September 2026, Stereotaxis, Inc. (STXS) is classified as HALAL by Maz Vantage: it passes all 5 published Shariah screening standards it was tested against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
Yes. Stereotaxis, Inc. is within every AAOIFI limit: debt and interest-bearing cash and investments under 30% of its 36-month average market cap, and interest income under 5% of revenue.
About 0.37% of each dividend: Stereotaxis, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.